NCT05061251 is a EARLY_PHASE1 clinical trial of BAY 2402234 in Glioma, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT05061251?

NCT05061251 is sponsored by University of Texas Southwestern Medical Center.

What drugs are being tested in NCT05061251?

Interventions in NCT05061251: BAY 2402234.

What condition does NCT05061251 study?

NCT05061251 studies Glioma, IDH Mutation.

Is NCT05061251 still recruiting?

NCT05061251 is currently withdrawn. Last updated 11 January 2022.

Last reviewed 2022-01-11 · How we verify

NCT05061251

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma

Withdrawn EARLY_PHASE1 Last updated 11 January 2022

What this trial tests

EARLY_PHASE1 trial testing BAY 2402234 in Glioma. Withdrawn.

Timeline

1 December 2021

Primary endpoint
1 December 2022

1 December 2023

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Phase	EARLY_PHASE1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 December 2021
Primary completion	1 December 2022
Estimated completion	1 December 2023

Drugs / interventions tested

BAY 2402234 — full drug profile →

Conditions studied

Glioma — all drugs for Glioma →
IDH Mutation — all drugs for IDH Mutation →

Sponsor

University of Texas Southwestern Medical Center

Who can join

18 and older, any sex, with Glioma or IDH Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to look at how BAY 2402234 responds in body in patients with recurrent glioma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

DHODH-mediated mitochondrial redox homeostasis: a novel ferroptosis regulator and promising therapeutic target.
Cao J, Chen X, Chen L, Lu Y, et al · · 2025 · cited 23× · PMID 40716151 · DOI 10.1016/j.redox.2025.103788
Metabolomic and Lipidomic Profiling of Gliomas-A New Direction in Personalized Therapies.
Gaca-Tabaszewska M, Bogusiewicz J, Bojko B. · · 2022 · cited 20× · PMID 36291824 · DOI 10.3390/cancers14205041
Metabolism and signaling crosstalk in glioblastoma progression and therapy resistance.
Zarzuela L, Durán RV, Tomé M. · · 2025 · cited 9× · PMID 38105543 · DOI 10.1002/1878-0261.13571
DHODH Inhibition Suppresses <i>MYC</i> and Inhibits the Growth of Medulloblastoma in a Novel In Vivo Zebrafish Model.
Tsea I, Olsen TK, Polychronopoulos PA, Tümmler C, et al · · 2024 · cited 4× · PMID 39766063 · DOI 10.3390/cancers16244162
Current and emerging therapies in IDH-mutant glioma.
Nakhate V, Youssef G, Wen PY. · · 2026 · PMID 42085879 · DOI 10.1016/j.neurot.2026.e00913
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.
Nan Y, Wang K, Hu M, Luo Q, et al · · 2026 · PMID 41735312 · DOI 10.1038/s41467-026-70001-5

Verify or expand the search:

Other recruiting trials for Glioma

Currently open trials in the same condition.

NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
NCT07450872 — Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors · recruiting
NCT07405372 — Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas · recruiting
NCT07338539 — BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM · Phase 2 · recruiting

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05061251 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 11 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05061251.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing